FAQ: Lantern Pharma's AI Module for Accelerating Cancer Combination Therapies Development

What is the purpose of Lantern Pharma’s new AI module?

The new AI module is designed to predict the efficacy of combination therapies involving DNA-damaging agents and DNA damage response inhibitors, aiming to accelerate the development of targeted cancer treatments.

How does the AI module reduce development time and cost?

By enabling precise, biomarker-guided design of cancer treatment regimens, the tool can reduce development time and cost by up to one-third.

What evidence supports the effectiveness of Lantern Pharma’s AI module?

The tool is backed by a peer-reviewed analysis of 221 clinical trials, demonstrating its capability in designing effective cancer treatment regimens.

Can you provide an example of how the AI module has been used?

The platform guided the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer combining LP-184 and olaparib.

What is Lantern Pharma’s RADR® platform?

RADR® is Lantern Pharma’s proprietary AI and machine learning platform that leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to accelerate oncology drug development.

How fast can Lantern Pharma advance drug programs from AI insights to clinical trials?

On average, Lantern’s newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years.

What is the cost per drug program for Lantern Pharma?

The cost per program is approximately $2.5 million, from initial AI insights to first-in-human clinical trials.

Is Lantern Pharma exploring opportunities to scale its AI system?

Yes, Lantern is exploring licensing and commercialization opportunities to scale the system across oncology indications.

Where can I find more information about Lantern Pharma and its developments?

The latest news and updates relating to Lantern Pharma (LTRN) are available in the company’s newsroom at https://ibn.fm/LTRN.